[PDF][PDF] Different prognostic value of cytokeratin-19 mRNA–positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer
M Ignatiadis, N Xenidis, M Perraki… - Journal of clinical …, 2007 - researchgate.net
M Ignatiadis, N Xenidis, M Perraki, S Apostolaki, E Politaki, M Kafousi, EN Stathopoulos…
Journal of clinical oncology, 2007•researchgate.netDifferent Prognostic Value of Cytokeratin-19 mRNA–Positive Circulating Tumor Cells
According to Estrogen Receptor and HER2 Sta Page 1 Different Prognostic Value of
Cytokeratin-19 mRNA–Positive Circulating Tumor Cells According to Estrogen Receptor and
HER2 Status in Early-Stage Breast Cancer Michail Ignatiadis, Nikos Xenidis, Maria Perraki,
Stella Apostolaki, Eleni Politaki, Maria Kafousi, Efstathios N. Stathopoulos, Aliki Stathopoulou,
Evi Lianidou, Grigorios Chlouverakis, Christos Sotiriou, Vassilis Georgoulias, and Dimitris …
According to Estrogen Receptor and HER2 Sta Page 1 Different Prognostic Value of
Cytokeratin-19 mRNA–Positive Circulating Tumor Cells According to Estrogen Receptor and
HER2 Status in Early-Stage Breast Cancer Michail Ignatiadis, Nikos Xenidis, Maria Perraki,
Stella Apostolaki, Eleni Politaki, Maria Kafousi, Efstathios N. Stathopoulos, Aliki Stathopoulou,
Evi Lianidou, Grigorios Chlouverakis, Christos Sotiriou, Vassilis Georgoulias, and Dimitris …
Purpose
To examine the prognostic value of cytokeratin-19 (CK-19) mRNA–positive circulating tumor cells (CTCs) in early-stage breast cancer patients focusing on clinically relevant subgroups based on estrogen receptor (ER) and HER2 expression.
researchgate.net